Ashwin Srinivasan Kumar, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Losartan | 4 | 2024 | 262 | 0.280 |
Why?
|
| Physical Conditioning, Animal | 2 | 2024 | 363 | 0.210 |
Why?
|
| Latent Tuberculosis | 1 | 2024 | 223 | 0.180 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2021 | 189 | 0.180 |
Why?
|
| Receptors, CXCR3 | 1 | 2021 | 240 | 0.170 |
Why?
|
| Running | 1 | 2024 | 489 | 0.160 |
Why?
|
| Exercise Therapy | 2 | 2024 | 939 | 0.150 |
Why?
|
| Ascites | 1 | 2019 | 336 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2024 | 4648 | 0.110 |
Why?
|
| Stromal Cells | 1 | 2019 | 1335 | 0.110 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2024 | 1911 | 0.100 |
Why?
|
| Tuberculosis | 1 | 2024 | 2011 | 0.090 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 3944 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2023 | 3461 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 5446 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 21178 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11872 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 4903 | 0.050 |
Why?
|
| Granuloma | 1 | 2024 | 329 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 6966 | 0.050 |
Why?
|
| Chemokine CXCL11 | 1 | 2021 | 42 | 0.050 |
Why?
|
| Leucovorin | 1 | 2023 | 644 | 0.050 |
Why?
|
| Chemokine CXCL9 | 1 | 2021 | 135 | 0.050 |
Why?
|
| Mice | 6 | 2024 | 81912 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2021 | 719 | 0.040 |
Why?
|
| Edema | 1 | 2023 | 764 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2021 | 431 | 0.040 |
Why?
|
| Animals | 7 | 2024 | 168965 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2023 | 1652 | 0.040 |
Why?
|
| Rabbits | 1 | 2024 | 4751 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 13650 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2023 | 1626 | 0.030 |
Why?
|
| Antitubercular Agents | 1 | 2024 | 1380 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2023 | 2900 | 0.030 |
Why?
|
| Neoplasms | 1 | 2024 | 22350 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2019 | 1759 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 17097 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2023 | 2322 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2021 | 3154 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2023 | 3468 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 2902 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2019 | 1407 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 1733 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 18330 | 0.020 |
Why?
|
| Collagen | 1 | 2019 | 2636 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3608 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2021 | 2745 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2023 | 3114 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8535 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 2627 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2019 | 3561 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5332 | 0.020 |
Why?
|
| Humans | 7 | 2024 | 767040 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2021 | 14476 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 11217 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 22361 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2019 | 3792 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 8628 | 0.010 |
Why?
|
| Prognosis | 1 | 2019 | 29963 | 0.010 |
Why?
|
| Female | 3 | 2023 | 396660 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 23621 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 65295 | 0.010 |
Why?
|
| Male | 1 | 2021 | 364203 | 0.000 |
Why?
|